Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Colorectal Neoplasms 19Carcinoma, Hepatocellular 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Nasopharyngeal Neoplasms 4

Interventions

pembrolizumab 4toripalimab 2tislelizumab 1spartalizumab 1sintilimab 1efineptakin alfa 1camrelizumab 1atezolizumab 1Taxes 1MK 2206 1Injections 1Cyclophosphamide 1Cetuximab 1Albumin-Bound Paclitaxel 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced or Metastatic Solid Tumors × spartalizumab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡